A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Trial Profile

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Tisotumab-vedotin (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Genmab
  • Most Recent Events

    • 25 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2018 According to a Seattle Genetics media release, data from this trial will be presented at the American Society of Clinical Oncology 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top